Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.

Haematologica 2011 Jan 7;96(1):163-6. Epub 2010 Oct 7.

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.

Dasatinib is considered an effective drug in imatinib-resistant chronic myeloid leukemia. Although reported to be well-tolerated, severe events such as pleural or pericardial effusion have been reported at 140 mg daily. We examined our chronic myeloid leukemia patients treated with dasatinib at 100 mg or 50 mg daily and identified 4 of 13 patients who developed marked effusion formation. In 2 patients, grade III/IV pleural and/or pericardial effusions were recorded. All 4 patients had received previous anti-leukemia therapy but none had pre-existing cardiac or pulmonary diseases. In 3 patients, dasatinib had to be discontinued despite treatment with diuretics and glucocorticosteroids. In conclusion, dasatinib-treated chronic myeloid leukemia patients are at risk for the development of pleural and pericardial effusions even when the drug is administered at 100 mg or 50 mg daily. Therefore, all patients should be examined for pre-existing comorbidity and risk factors before starting dasatinib and all should have repeated chest X-rays during long-term dasatinib therapy.

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2010.030494DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012781PMC
January 2011
12 Reads

Publication Analysis

Top Keywords

myeloid leukemia
16
chronic myeloid
16
pleural pericardial
12
100 daily
12
leukemia patients
8
dasatinib 100
8
pericardial effusion
8
pericardial effusions
8
patients
7
dasatinib
6
comorbidity risk
4
patients developed
4
and/or pericardial
4
pleural and/or
4
effusions recorded
4
recorded patients
4
received previous
4
patients received
4
pre-existing comorbidity
4
iii/iv pleural
4

Similar Publications